Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3 -ITD–Mutated AML

米多司他林 医学 内科学 肿瘤科 移植 Fms样酪氨酸激酶3 癌症研究 帕纳替尼 索拉非尼 胃肠病学 造血干细胞移植 髓系白血病 白血病 无进展生存期 养生
作者
Richard T. Maziarz,Mrinal M. Patnaik,Bart L. Scott,Sanjay R. Mohan,Abhinav Deol,Scott D. Rowley,Dennis Dong Hwan Kim,Kelly Haines,Gaetano Bonifacio,Patrice Rine,Das Purkayastha,Hugo F. Fernandez
出处
期刊:Blood [Elsevier BV]
卷期号:132: 662-662 被引量:49
标识
DOI:10.1182/blood-2018-99-113582
摘要

Abstract Introduction: Midostaurin, a multitargeted tyrosine kinase inhibitor (TKI), plus induction and consolidation chemotherapy followed by single-agent midostaurin maintenance therapy resulted in significant benefits in event-free and overall survival (OS) in adults with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) compared with placebo (RATIFY study; Stone et al, N Engl J Med, 2017). In RATIFY, patients who received allogeneic hematopoietic stem cell transplant (alloSCT) did not receive midostaurin maintenance. Despite alloSCT providing the highest likelihood of sustained remission, relapse rates remain high (30%-59%; Schiller et al, Biol Blood Marrow Transplant, 2016), especially in patients with FLT3-internal tandem duplication-positive (ITD+) AML. Posttransplant maintenance therapy may improve this outcome. Here, we report the primary results from RADIUS, a randomized, open-label, phase 2 exploratory trial (NCT01883362) that investigated whether the addition of midostaurin to standard of care (SOC) after alloSCT could reduce the risk of relapse in patients with FLT3-ITD+ AML. Methods: Adults (aged 18-70 y) who had undergone myeloablative alloSCT in first complete remission (CR1), had achieved hematologic recovery, and were transfusion independent were eligible. Patients enrolled postengraftment and were randomized to receive SOC with or without midostaurin 50 mg twice daily continuously (4-week cycles) for up to 12 cycles. Study treatment started 28 to 60 days post-alloSCT and patients were followed for ≥24 months post-alloSCT. The primary endpoint was relapse-free survival (RFS) at 18 months post-alloSCT. Secondary endpoints included safety and disease-free survival (DFS), OS, and RFS at 24 months post-alloSCT. The study was not adequately powered to detect a statistical difference between the 2 arms; a sample size of 60 was calculated to detect a 50% reduction in the risk of relapse. Results: 60 patients were randomized (30 per arm). Baseline characteristics were generally balanced between the 2 arms. Overall, 30 patients completed 12 cycles of study treatment (14 with SOC; 16 with midostaurin). The median exposure to midostaurin was 10.5 months (range, 0.2 to 12.0 months) and the median dose intensity was 93 mg/day (range, 15-100 mg/day). Early treatment discontinuations were similar between arms (15 in the SOC arm; 13 in the midostaurin arm), frequently due to adverse events (AEs; 3% vs 23%) and consent withdrawal (20% vs 7%). Among 6 patients who withdrew consent in the SOC arm, 2 did so to pursue other TKI therapies. Midostaurin dose modifications occurred in 19 patients (63%), mostly due to AEs (84%); 1 instance was due to receiving a concomitant CYP3A4 inhibitor. With an estimated 18-month RFS (95% CI) of 76% (54%-88%) in the SOC arm and 89% (69%-96%) in the midostaurin arm, estimated relapse rates were 24% and 11%, respectively, which is a 46% relative reduction in the risk of relapse with the addition of midostaurin (Figure 1). At 18 months, the median RFS was not reached in either arm. Longer follow-up at 24 months (data not yet matured) will be presented, including RFS, OS, and DFS. In the SOC and midostaurin arms, AEs were reported in 87% and 100% of patients, respectively (the most common any-grade AE was vomiting: 23% vs 73%; Figure 2); serious AEs were reported in 57% and 30% of patients, respectively, with diarrhea (7% vs 13%), nausea (10% vs 3%), vomiting (10% vs 3%), and pyrexia (7% vs 7%) being the most common. Overall, 8 patients discontinued midostaurin therapy due to AEs (mostly gastrointestinal related) and 12 died on study (all during the follow-up phase; 8 in the SOC arm and 4 in the midostaurin arm [n=4 vs n=2 due to AML disease progression]). Rates of graft-vs-host disease (GVHD) were generally similar between the SOC and midostaurin arms (overall, 70% vs 73%; acute GVHD, 53% vs 57% [grade 2/3 events: 37% vs 30%; no grade 4 events]; chronic GVHD, 47% vs 37% [most events were mild or moderate; severe events: 1 with SOC and 2 with midostaurin]). Conclusions: Adding midostaurin to SOC reduced the risk of relapse at 18 months post-alloSCT by 46% (vs SOC). The safety profile of single-agent midostaurin was consistent with previous reports; no major safety concerns were identified when adding midostaurin to SOC following alloSCT. These data suggest that midostaurin monotherapy can be safely administered for ≤1 year and may improve outcomes in patients who undergo alloSCT in CR1. Disclosures Maziarz: Novartis Pharmaceuticals Corporation: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Incyte: Consultancy, Honoraria; Juno Therapeutics: Consultancy, Honoraria; Kite Therapeutics: Honoraria; Athersys, Inc.: Patents & Royalties. Scott: Agios: Consultancy; Novartis: Research Funding; Celgene: Consultancy, Research Funding; Alexion: Consultancy. Deol: Kite Pharmaceuticals: Consultancy; Novartis: Consultancy. Kim: Novartis: Consultancy, Honoraria, Research Funding; Briston-Meyers Squibb: Consultancy, Honoraria, Research Funding; Paladin: Consultancy; Pfizer: Consultancy. Haines: Novartis: Employment. Bonifacio: Novartis: Employment. Rine: Novartis: Employment. Purkayastha: Novartis Pharmaceuticals Corporation: Employment.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zhuxd完成签到,获得积分10
1秒前
1秒前
105完成签到 ,获得积分10
1秒前
liu完成签到,获得积分10
1秒前
彭洪凯完成签到,获得积分10
2秒前
得鹿梦鱼完成签到,获得积分10
3秒前
闪闪的斑马完成签到,获得积分10
5秒前
张大星完成签到 ,获得积分10
5秒前
万能图书馆应助尘南浔采纳,获得10
5秒前
迷人的小土豆完成签到,获得积分10
5秒前
6秒前
啦啦啦啦啦完成签到 ,获得积分10
6秒前
虚幻的香彤完成签到,获得积分10
8秒前
Qing发布了新的文献求助10
9秒前
10秒前
聪慧的凝海完成签到 ,获得积分10
10秒前
一点完成签到,获得积分10
13秒前
13秒前
pp完成签到,获得积分10
13秒前
13秒前
14秒前
霸气南珍完成签到,获得积分10
14秒前
孤独衣完成签到,获得积分10
15秒前
尘南浔发布了新的文献求助10
15秒前
SciGPT应助mojie62采纳,获得10
16秒前
satchzhao完成签到,获得积分10
16秒前
稳重完成签到 ,获得积分10
17秒前
柠檬很酸发布了新的文献求助10
18秒前
屠夫9441完成签到 ,获得积分10
18秒前
liuuuuuu完成签到,获得积分10
18秒前
烟雨发布了新的文献求助10
18秒前
高高的天亦完成签到 ,获得积分10
19秒前
exquisite完成签到,获得积分10
19秒前
勤劳滑板完成签到 ,获得积分10
19秒前
merrylake完成签到 ,获得积分10
19秒前
安静的乐松完成签到,获得积分10
19秒前
小雯关注了科研通微信公众号
20秒前
单薄月饼完成签到,获得积分10
20秒前
晚灯君完成签到 ,获得积分10
20秒前
复杂真完成签到,获得积分10
21秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968578
求助须知:如何正确求助?哪些是违规求助? 3513406
关于积分的说明 11167631
捐赠科研通 3248853
什么是DOI,文献DOI怎么找? 1794499
邀请新用户注册赠送积分活动 875150
科研通“疑难数据库(出版商)”最低求助积分说明 804671